186 related articles for article (PubMed ID: 36192478)
21. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
Ramírez-Moya J; Wert-Lamas L; Santisteban P
Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
24. PTEN inhibits BMI1 function independently of its phosphatase activity.
Fan C; He L; Kapoor A; Rybak AP; De Melo J; Cutz JC; Tang D
Mol Cancer; 2009 Nov; 8():98. PubMed ID: 19903340
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer.
Nip H; Dar AA; Saini S; Colden M; Varahram S; Chowdhary H; Yamamura S; Mitsui Y; Tanaka Y; Kato T; Hashimoto Y; Shiina M; Kulkarni P; Dasgupta P; Imai-Sumida M; Tabatabai ZL; Greene K; Deng G; Dahiya R; Majid S
Oncotarget; 2016 Oct; 7(42):68371-68384. PubMed ID: 27634912
[TBL] [Abstract][Full Text] [Related]
26. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
27. PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Errafiy R; Aguado C; Ghislat G; Esteve JM; Gil A; Loutfi M; Knecht E
PLoS One; 2013; 8(12):e83318. PubMed ID: 24349488
[TBL] [Abstract][Full Text] [Related]
28. CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells.
Rhee YH; Chung PS; Kim SH; Ahn JC
Biochem Biophys Res Commun; 2014 May; 447(4):557-62. PubMed ID: 24525130
[TBL] [Abstract][Full Text] [Related]
29. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
[TBL] [Abstract][Full Text] [Related]
30. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
31. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
[TBL] [Abstract][Full Text] [Related]
32. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
33. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
[TBL] [Abstract][Full Text] [Related]
34. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.
Beckham TH; Cheng JC; Lu P; Marrison ST; Norris JS; Liu X
PLoS One; 2013; 8(10):e76593. PubMed ID: 24098536
[TBL] [Abstract][Full Text] [Related]
35. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
[TBL] [Abstract][Full Text] [Related]
36. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
Nacerddine K; Beaudry JB; Ginjala V; Westerman B; Mattiroli F; Song JY; van der Poel H; Ponz OB; Pritchard C; Cornelissen-Steijger P; Zevenhoven J; Tanger E; Sixma TK; Ganesan S; van Lohuizen M
J Clin Invest; 2012 May; 122(5):1920-32. PubMed ID: 22505453
[TBL] [Abstract][Full Text] [Related]
37. NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway.
Eide PW; Cekaite L; Danielsen SA; Eilertsen IA; Kjenseth A; Fykerud TA; Ågesen TH; Bruun J; Rivedal E; Lothe RA; Leithe E
Cell Signal; 2013 Jan; 25(1):12-8. PubMed ID: 22974840
[TBL] [Abstract][Full Text] [Related]
38. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
39.
Lu XX; Cao LY; Chen X; Xiao J; Zou Y; Chen Q
Biomed Res Int; 2016; 2016():2476842. PubMed ID: 27822469
[No Abstract] [Full Text] [Related]
40. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nakahata S; Ichikawa T; Maneesaay P; Saito Y; Nagai K; Tamura T; Manachai N; Yamakawa N; Hamasaki M; Kitabayashi I; Arai Y; Kanai Y; Taki T; Abe T; Kiyonari H; Shimoda K; Ohshima K; Horii A; Shima H; Taniwaki M; Yamaguchi R; Morishita K
Nat Commun; 2014 Feb; 5():3393. PubMed ID: 24569712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
